A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

@article{Bramhall2002ADP,
  title={A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer},
  author={Simon R. Bramhall and J. Schulz and John J. Nemunaitis and P D Brown and M. Baillet and John A. C. Buckels},
  journal={British Journal of Cancer},
  year={2002},
  volume={87},
  pages={161 - 167}
}
Pancreatic cancer is the fifth most common cause of cancer death in the western world and the prognosis for unresectable disease remains poor. Recent advances in conventional chemotherapy and the development of novel ‘molecular’ treatment strategies with different toxicity profiles warrant investigation as combination treatment strategies. This randomised study in pancreatic cancer compares marimastat (orally administered matrix metalloproteinase inhibitor) in combination with gemcitabine to… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 215 CITATIONS, ESTIMATED 55% COVERAGE

The Roles of Matrix Metalloproteinases in Pancreatic Cancer.

  • Progress in molecular biology and translational science
  • 2017
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Modelling prognostic factors in advanced pancreatic cancer

  • British Journal of Cancer
  • 2008
VIEW 5 EXCERPTS
CITES METHODS & BACKGROUND

Anti-angiogenesis therapy in pancreatic carcinoma.

  • JOP : Journal of the pancreas
  • 2006
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Evolution of systemic therapy for advanced pancreatic cancer.

  • Expert review of anticancer therapy
  • 2010
VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

Targeted therapies for pancreatic cancer.

  • British medical bulletin
  • 2008
VIEW 1 EXCERPT
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2003
2019

CITATION STATISTICS

  • 10 Highly Influenced Citations

  • Averaged 9 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Matrix metalloproteinase inhibition: a review of anti-tumour activity.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 1995
VIEW 1 EXCERPT